 Immunogenetic prediction pulmonary fibrosis systemic sclerosis systemic sclerosis patients pulmonary fibrosis autoantibodies MHC class II genes patients pulmonary fibrosis HLA vs patients pulmonary fibrosis presence relative risk development pulmonary fibrosis patient scleroderma risk substantial careful monitoring patients treatment early stage disease